These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15610126)

  • 1. Mind over matter: CNS-based approaches to urological diseases.
    Wyllie MG
    BJU Int; 2004 Dec; 94(9):1389-90. PubMed ID: 15610126
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract.
    Hiyama T; Yoshihara M; Tanaka S; Haruma K; Chayama K
    J Gastroenterol Hepatol; 2009 Apr; 24(4):537-46. PubMed ID: 19220673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 'level playing field' for urological disorders. Who sets the rules?
    Wyllie MG
    BJU Int; 2010 Oct; 106(7):1089-90. PubMed ID: 20840319
    [No Abstract]   [Full Text] [Related]  

  • 4. Axel Unterbeck on memory, cognition and the development of CNS drugs. Interview by Steve Carney.
    Unterbeck A
    Drug Discov Today; 2005 Feb; 10(3):165-8. PubMed ID: 15708528
    [No Abstract]   [Full Text] [Related]  

  • 5. Creation of a de novo, pharmaceutical company with a urological bent.
    Wyllie MG
    BJU Int; 2011 Nov; 108(9):E310-1. PubMed ID: 22023062
    [No Abstract]   [Full Text] [Related]  

  • 6. Special issue on CNS experimental medicine.
    Dawson GR; Dourish CT; Goodwin GM
    J Psychopharmacol; 2011 Sep; 25(9):1145-7. PubMed ID: 21994313
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in neuroscience.
    Williams M
    Curr Opin Investig Drugs; 2003 Jan; 4(1):26-7. PubMed ID: 12625023
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of pharmacogenetics in treating central nervous system disorders.
    Patnaik M; Renda MJ; Athanasiou MC; Reed CR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's the point?
    Wyllie MG
    BJU Int; 2006 Mar; 97(3):649-50. PubMed ID: 16469042
    [No Abstract]   [Full Text] [Related]  

  • 12. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The interaction of drugs acting predominantly on the CNS].
    Zelikson IuI; Davydova ON
    Med Sestra; 1988 Nov; 47(11):45-52. PubMed ID: 3221755
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of pharmacogenetics in the use of CNS drugs: from drug pipeline to primary care?
    Hopkins MM; Martin PA
    Expert Rev Neurother; 2006 Dec; 6(12):1765-7. PubMed ID: 17181421
    [No Abstract]   [Full Text] [Related]  

  • 15. Just hold on a minute (or should it be two?).
    Wyllie MG
    BJU Int; 2006 Jul; 98(1):227-8. PubMed ID: 16831172
    [No Abstract]   [Full Text] [Related]  

  • 16. Ebbing and flowing.
    Wyllie MG
    BJU Int; 2007 Nov; 100(5):1189-90. PubMed ID: 17922790
    [No Abstract]   [Full Text] [Related]  

  • 17. The drug-device continuum in the management of urological disease.
    Wyllie MG
    BJU Int; 2008 May; 101(9):1179-80. PubMed ID: 18399833
    [No Abstract]   [Full Text] [Related]  

  • 18. CNS research in the pharmaceutical industry. A personal view of how innovation could be promoted by clinical pharmacology.
    Horowski R
    Eur J Clin Pharmacol; 1995; 47(5):467-8. PubMed ID: 7720772
    [No Abstract]   [Full Text] [Related]  

  • 19. Back to the future for urological drug development?
    Wyllie MG
    BJU Int; 2005 Apr; 95(6):899-900. PubMed ID: 15794806
    [No Abstract]   [Full Text] [Related]  

  • 20. Is urological drug discovery in the doldrums?
    Wyllie MG
    BJU Int; 2005 May; 95(7):1109-10. PubMed ID: 15839942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.